Introduction: Our study delves into the intricate interplay of risk factors and the strategic selection of adjuvant therapy, scrutinizing their influence on recurrence and survival outcomes in stage IIA (T3N0M0) colon cancer patients. Materials and Methods: The study examined the medical records of patients who underwent surgery for stage IIA colon cancer. Identification of stage IIA (pT3N0M0) colon cancer involved a comprehensive review of postoperative clinical records and histological reports. Parameters such as demographic data, tumor characteristics, microsatellite instability status, tumor locations, recurrence risk factors, preoperative carcinoembryonic antigen levels, and adjuvant treatments were systematically evaluated. Results: In our study involving 220 patients, 138 were male (62.7%), with a median age of 62 years and a median body mass index of 25.1 kg/m2. In the patient group without risk factors, no statistically significant difference was detected in disease-free survival (DFS) rates between those who received treatment and those who did not (p = 0.546). DFS rates of patients with >1 risk factor were statistically significantly lower than those with a single risk factor (p = 0.017). In patients with >1 risk factor, the DFS of those who did not receive adjuvant treatment was significantly lower than those who received adjuvant treatment (p < 0.001). In the patient group with recurrence, when adjuvant treatments were considered, recurrence was significantly higher in the group receiving capecitabine (p = 0.01). Conclusion: The decision for adjuvant chemotherapy in stage IIA colon cancer patients involves careful consideration of various parameters and risk factors. The evolving landscape of research may refine recommendations, ensuring optimal treatment outcomes while minimizing unnecessary toxicity.

Journal Section:
Clinical Study
Keywords:
Colon cancer, Stage IIA, Adjuvant chemotherapy, Risk factors, Recurrence
1.
Siegel
RL
,
Miller
KD
,
Goding Sauer
A
,
Fedewa
SA
,
Butterly
LF
,
Anderson
JC
, et al.
Colorectal cancer statistics, 2020
.
J Clin
.
2020
;
70
(
3
):
145
–
64
.
Google Scholar
 
2.
Jessup
JM
,
McGinnis
LS
,
Steele
GD
,
Menck
HR
,
Winchester
DP
.
The national cancer data base. Report on colon cancer
.
Rep colon Cancer Cancer
.
1996
;
78
(
4
):
918
–
26
.
Google Scholar
 
3.
Sobin
LH
,
Gaspodarowicz
MK
,
Wittekind
C
.
TNM classification of malignant tumors
. 7th ed.
New York, NY
:
Wiley-Blackwell
;
2009
.
Google Scholar
 
4.
De Rosa
M
,
Pace
U
,
Rega
D
,
Costabile
V
,
Duraturo
F
,
Izzo
P
, et al.
Genetics, diagnosis and management of colorectal cancer (Review)
.
Oncol Rep
.
2015
;
34
(
3
):
1087
–
96
.
Google Scholar
 
5.
Argiles
G
,
Tabernero
J
,
Labianca
R
,
Hochhauser
D
,
Salazar
R
,
Iveson
T
, et al.
Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up
.
Ann Oncol
.
2020
;
31
(
10
):
1291
–
305
.
Google Scholar
 
6.
Benson
AB
,
Venook
AP
,
Al-Hawary
MM
,
Cederquist
L
,
Chen
YJ
,
Ciombor
KK
, et al.
NCCN guidelines insights: colon cancer, version 2.2018
.
J Natl Compr Canc Netw
.
2018
;
16
(
4
):
359
–
69
.
Google Scholar
 
7.
Labianca
R
,
Nordlinger
B
,
Beretta
GD
,
Mosconi
S
,
Mandalà
M
,
Cervantes
A
, et al.
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
.
2013
;
24
(
Suppl 6
):
vi64
–
72
.
Google Scholar
 
8.
Rd
BA
,
Schrag
D
,
Somerfield
MR
,
Cohen
AM
,
Figueredo
AT
,
Flynn
PJ
, et al.
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
.
J Clin Oncol
.
2004
;
22
(
16
):
3408
–
19
.
Google Scholar
 
9.
Meyers
BM
,
Cosby
R
,
Quereshy
F
,
Jonker
D
.
Adjuvant chemotherapy for stage II and III colon cancer following complete resection: a cancer care ontario systematic review
.
Clin Oncol
.
2017
;
29
(
7
):
459
–
65
.
Google Scholar
 
10.
Kumar
A
,
Kennecke
HF
,
Renouf
DJ
,
Lim
HJ
,
Gill
S
,
Ryan
W
, et al.
Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer
.
Cancer
.
2015
;
121
(
4
):
527
–
34
.
Google Scholar
 
11.
Thierry
A´
,
Boni
C
,
Navarro
M
,
Tabernero
J
,
Hickish
T
,
Topham
C
, et al.
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
.
J Clin Oncol
.
2009
;
27
(
19
):
3109
–
16
.
Google Scholar
 
12.
André
T
,
Meyerhardt
J
,
Iveson
T
,
Sobrero
A
,
Yoshino
T
,
Souglakos
I
, et al.
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
.
Lancet Oncol
.
2020
;
21
(
12
):
1620
–
9
.
Google Scholar
 
13.
Grothey
A
,
Sobrero
AF
,
Shields
AF
,
Yoshino
T
,
Paul
J
,
Taieb
J
, et al.
Duration of adjuvant chemotherapy for stage III colon cancer
.
N Engl J Med
.
2018
;
378
(
13
):
1177
–
88
.
Google Scholar
 
14.
Tie
J
,
Cohen
JD
,
Lahouel
K
,
Lo
SN
,
Wang
Y
,
Kosmider
S
, et al.
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer
.
N Engl J Med
.
2022
;
386
(
24
):
2261
–
72
.
Google Scholar
 
15.
Hang To
Y
,
Gibbs
P
,
Tie
J
,
Loree
J
,
Glyn
T
,
Degeling
K
.
Circulating tumour DNA guided adjuvant chemotherapy decision making in stage II colon cancer–a clinical vignette study
.
Cancers
.
2023
;
15
(
21
):
5227
.
Google Scholar
 
16.
Olivier
T
,
Haslam
A
,
Prasad
V
.
Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
.
BMC Med
.
2023
;
21
(
1
):
344
.
Google Scholar
 
17.
Sakin
A
,
Yasar
N
,
Sahin
S
,
Arici
S
,
Secmeler
S
,
Can
O
, et al.
Efficacy and tolerability of adjuvant therapy in ≥70-year-old patients with T3N0M0 colorectal cancer: an observational study
.
J Oncol Pharm Pract
.
0
(
0
):
1
–
13
.
18.
Extermann
M
,
Boler
I
,
Reich
R
,
Lyman
GH
,
Brown
RH
,
DeFelice
J
, et al.
Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score
.
Cancer
.
2012
;
118
(
13
):
3377
–
86
.
Google Scholar
 
19.
Lewis
A
,
Reed
M
,
Walde
N
,
Voutsadakis
IA
.
An evaluation of the Index4 tool for chemotherapy toxicity prediction in cancer patients older than 70 years old
.
Sci Rep
.
2023
;
13
(
1
):
1082
.
Google Scholar
 
20.
Achilli
P
,
Crippa
J
,
Grass
F
,
Mathis
KL
,
D’Angelo
A-LD
,
Abd El Aziz
MA
, et al.
Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: analysis of the National Cancer Database
.
Int J Cancer
.
2020
;
148
:
161
–
9
.
Google Scholar
 
21.
QUASAR Collaborative Group
;
Gray
R
,
Barnwell
J
,
McConkey
C
,
Hills
RK
,
Williams
NS
, et al.
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
.
Lancet
.
2007
;
370
(
9604
):
2020
–
9
.
Google Scholar
 
22.
Wilkinson
NW
,
Yothers
G
,
Lopa
S
,
Costantino
JP
,
Petrelli
NJ
,
Wolmark
N
.
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials
.
Ann Surg Oncol
.
2010
;
17
(
4
):
959
–
66
.
Google Scholar
 
23.
Enofe
N
,
Morris
AD
,
Liu
Y
,
Liang
W
,
Wu
CS
,
Sullivan
PS
, et al.
Receipt of adjuvant chemotherapy in stage II colon cancer and overall survival: a national cancer database study
.
J Surg Res
.
2020
;
252
:
69
–
79
.
Google Scholar
 
24.
Yang
Y
,
Yang
Y
,
Yang
H
,
Wang
F
,
Wang
H
,
Qi
C
, et al.
Adjuvant chemotherapy for stage II colon cancer: who really needs it
.
Cancer Manag Res
.
2018
;
10
:
2509
–
20
.
Google Scholar
 
25.
Shinto
E
,
Oki
E
,
Shimokawa
M
,
Yamaguchi
S
,
Ishiguro
M
,
Hasegawa
S
, et al.
Enhanced clinical utility of molecular budding signature as a recurrence risk determinant in stage II and III colon cancer patients
.
Ann Surg Oncol
.
2023
;
30
(
8
):
5239
–
47
.
Google Scholar
 
26.
Barresı1
V
,
Reggıanı Bonettı
L
,
Ienı
A
,
Branca
G
,
Tuccarı
G
.
Histologic prognostic markers in stage IIA colorectal cancer: a comparative study
.
Scand J Gastroenterol
.
2016
;
51
(
3
):
314
–
20
.
Google Scholar
 
27.
Babcock
BD
,
Aljehani
MA
,
Jabo
B
,
Choi
AH
,
Morgan
JW
,
Selleck
MJ
, et al.
High-risk stage II colon cancer: not all risks are created equal
.
Ann Surg Oncol
.
2018
;
25
(
7
):
1980
–
5
.
Google Scholar
 
28.
Kim
MK
,
Won
DD
,
Sun
MP
,
Kim
T
,
Kim
SR
,
Oh
ST
, et al.
Effect of adjuvant chemotherapy on stage II colon cancer: analysis of Korean national data
.
Cancer Res Treat
.
2018
;
50
(
4
):
1149
–
63
.
Google Scholar
 
29.
Lin
C-C
,
Lin
J-K
,
Chang
S-C
,
Wang
H-S
,
Yang
S-H
,
Jiang
J-K
, et al.
Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute
.
Int J Colorectal Dis
.
2009
;
24
(
6
):
665
–
76
.
Google Scholar
 
30.
Quah
H-M
,
Chou
JF
,
Gonen
M
,
Shia
J
,
Schrag
D
,
Landmann
RG
, et al.
Identification of patients with high-risk stage II colon cancer for adjuvant therapy
.
Dis Colon Rectum
.
2008
;
51
(
5
):
503
–
7
.
Google Scholar
 
31.
Koenig
JL
,
Toesca
DAS
,
Harris
JP
,
Tsai
CJ
,
Haraldsdottir
S
,
Lin
AY
, et al.
Microsatellite instability and adjuvant chemotherapy in stage II colon cancer
.
Am J Clin Oncol
.
2019
;
42
(
7
):
573
–
80
.
Google Scholar
 
32.
Parc
Y
,
Gueroult
S
,
Mourra
N
,
Serfaty
L
,
Fle´jou
J-F
,
Tiret
E
, et al.
Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer
.
Gut
.
2004
;
53
(
3
):
371
–
5
.
Google Scholar
 
33.
Dong
WB
,
Kang
BW
,
Lee
SJ
,
Kim
HJ
,
Park
SY
,
Park
JS
, et al.
Clinical implications of mismatch repair status in patients with high-risk stage II colon cancer
.
In Vivo
.
2019
;
33
(
2
):
649
–
57
.
Google Scholar
 
34.
Acar
T
,
Acar
N
,
Kamer
E
,
Cengiz
F
,
Tekindal
MA
,
Bağ
H
, et al.
Do tumor localization, microsatellite instability and mismatch repair deficiency have an impact on the prognosis of colorectal cancer
.
Niger J Clin Pract
.
2021
;
24
(
12
):
1814
–
23
.
Google Scholar
 
35.
Kim
H-G
,
Yang
SY
,
Han
YD
,
Cho
MS
,
Min
BS
,
Lee
KY
, et al.
Association of perioperative serum carcinoembryonic antigen level and recurrence in low-risk stage IIA colon cancer
.
PLoS One
.
2021
;
16
(
6
):
e0252566
.
Google Scholar
 
36.
Zhou
H
,
Wang
S
,
Cai
Z
,
Qiu
E
,
Chen
Q
,
Rao
X
, et al.
Adjuvant chemotherapy benefits on patients with elevated carcinoembryonic antigen in stage IIA colon cancer: a SEER-based analysis
.
Int J Colorectal Dis
.
2022
;
37
(
12
):
2481
–
9
.
Google Scholar
 
37.
Takeyama
H
,
Noura
S
,
Suzuki
Y
,
Odagiri
K
,
Yanagimoto
Y
,
Yamashita
M
, et al.
Higher body mass index is a simple favorable non-cancer prognostic marker for Japanese elderly colorectal cancer patients after curative resection
.
J Anus Rectum Colon
.
2022
;
6
(
2
):
134
–
42
.
Google Scholar
 
38.
Shahjehan
F
,
Merchea
A
,
Cochuyt
JJ
,
Li
Z
,
Colibaseanu
DT
,
Kasi
PM
.
Body mass index and long-term outcomes in patients with colorectal cancer
.
Front Oncol
.
2018
;
8
(
8
):
620
.
Google Scholar
 
39.
Sakin
A
,
Arici
S
,
Secmeler
S
,
Can
O
,
Geredeli
C
,
Yasar
N
, et al.
Prognostic significance of primary tumor localization in stage II and III colon cancer
.
World J Gastrointest Oncol
.
2018
;
10
(
11
):
410
–
20
.
Google Scholar
 
40.
Inoue
M
,
Kanemitsu
Y
,
Tsukamoto
S
,
Moritani
K
,
Takamizawa
Y
,
Daiko
H
.
Prognostic impact of primary tumour location after curative resection in Stage I-III colorectal cancer: a single-centre retrospective study
.
Jpn J Clin Oncol
.
2024
;
54
(
7
):
753
–
60
.
Google Scholar
 
41.
Mendis
S
,
Beck
S
,
Lee
B
,
Lee
M
,
Wong
R
,
Kosmider
S
, et al.
Right versus left sided metastatic colorectal cancer: teasing out clinicopathologic drivers of disparity in survival
.
Asia Pac J Clin Oncol
.
2019
;
15
(
3
):
136
–
43
.
Google Scholar
 
© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.